Threshold Pharma (THLD) to Discontinue Tarloxotinib Development; Will Refocus Resources

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/9/2026

1. HUM
2. SPCX
3. ALHC
4. T
5. PEP
6. CVS
7. UNH
8. TMUS
9. VZ
10. SPY

Go back to Threshold Pharma (THLD) to Discontinue Tarloxotinib Development; Will Refocus Resources

Threshold Pharmaceuticals Announces Interim Results from Tarloxotinib Program and its Plans to Focus on Evofosfamide and Earlier-Stage Opportunities

September 29, 2016 6:03 PM EDT

-- Tarloxotinib Primary Interim Response Rate Endpoint Achieved in Patients with Recurrent or Metastatic Squamous Cell Carcinoma of the Skin (SCCS) but not Achieved in Patients with Metastatic Squamous Cell Carcinoma of the Head and Neck (SCCHN) or Advanced EGFR-Mutant, T790M-Negative Non-Small Cell Lung Cancer (NSCLC); Company to Discontinue Investment in its Tarloxotinib Program --

-- Company to Focus on Evofosfamide in Combination with Immune Checkpoint Antibodies in Ongoing Collaboration with The University of Texas MD Anderson Cancer Center; Potential Registration of Evofosfamide in Japan, and IND-Enabling Studies of... More